<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2015.52004</article-id><article-id pub-id-type="publisher-id">WJCR-15032</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20150200000_49398984.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基质金属蛋白酶与胃癌侵袭和转移的研究进展
  The Research Progress of Matrix Metalloproteinases in Invasion and Metastasis of Gastric Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>熊</surname><given-names>亚立</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>向</surname><given-names>征</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆医科大学第一附属医院，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>425050668@qq.com(向征)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>04</month><year>2015</year></pub-date><volume>05</volume><issue>02</issue><fpage>21</fpage><lpage>26</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   侵袭和转移是胃癌最主要的生物学特征，也是导致治疗失败和患者死亡的主要原因，因此阻止胃癌的侵袭和转移在治疗过程中具有非常重要的意义。胃癌发生侵袭和转移，必须伴随细胞外基质和基底膜完整性的破坏、肿瘤细胞粘附能力的改变、血管生成，基质金属蛋白酶(matrix metalloproteinases, MMPs)则在其中扮演着重要的角色，目前以其作为治疗靶点的药物已进入临床试验阶段。本文就MMPs在胃癌侵袭和转移中的作用做一简单综述。&lt;br/&gt;As is known to all, the most important thing for treating gastric cancer is to prevent its invasion and metastasis, which are the most common causes of treatment failure and mortality. When invasion and metastasis happened, it always accompanied with the integrity destruction of the extracellular matrix and the basement membrane. And it often leads to the change of tumor cell adhesion ability and angiogenesis as well. Matrix metalloproteinases (MMPs) plays a significant role in the invasion and metastasis of gastric cancer. As a therapeutic target, the drugs affected on MMPs had reached the stage of clinical trials. I will make a simple review to introduce the role of MMPs in the invasion and metastasis of gastric cancer.
    
  
 
</p></abstract><kwd-group><kwd>胃癌，侵袭和转移，基质金属蛋白酶, Cancer of the Stomach</kwd><kwd> Invasion and Metastasis</kwd><kwd> Matrix Metalloproteinases</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>基质金属蛋白酶与胃癌侵袭和转移的研究进展<sup> </sup></title><p>熊亚立，向征<sup>*</sup></p><p>重庆医科大学第一附属医院，重庆</p><p>Email: <sup>*</sup>425050668@qq.com</p><p>收稿日期：2015年3月15日；录用日期：2015年3月27日；发布日期：2015年4月1日</p><disp-formula id="scirp.15032-formula498"><graphic xlink:href="http://html.hanspub.org/file/1-2150050x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>侵袭和转移是胃癌最主要的生物学特征，也是导致治疗失败和患者死亡的主要原因，因此阻止胃癌的侵袭和转移在治疗过程中具有非常重要的意义。胃癌发生侵袭和转移，必须伴随细胞外基质和基底膜完整性的破坏、肿瘤细胞粘附能力的改变、血管生成，基质金属蛋白酶(matrix metalloproteinases, MMPs)则在其中扮演着重要的角色，目前以其作为治疗靶点的药物已进入临床试验阶段。本文就MMPs在胃癌侵袭和转移中的作用做一简单综述。</p><p>关键词 :胃癌，侵袭和转移，基质金属蛋白酶</p><disp-formula id="scirp.15032-formula499"><graphic xlink:href="http://html.hanspub.org/file/1-2150050x7_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>随着我国生活习惯的改变和人口老龄化的加剧，肿瘤的发病率和死亡率也在逐年增加，胃癌是我国最常见的恶性肿瘤之一，死亡率居高不下。当临床上确诊为胃癌时，大多处于中晚期，多已形成转移灶，尤其是淋巴结的转移[<xref ref-type="bibr" rid="scirp.15032-ref1">1</xref>] 。近年来，随着综合治疗的应用，胃癌患者的生存时间有了一定的延长，但总的五年生存率仍只有20%~30%，治疗效果仍不能令人满意[<xref ref-type="bibr" rid="scirp.15032-ref2">2</xref>] 。侵袭和转移是胃癌患者死亡及手术治疗失败的主要原因。研究者在对胃癌的侵袭和转移机制的研究中发现，胃癌的组织细胞常伴有MMPs的过度表达和活性增高，它通过降解细胞外基质及基底膜，调节细胞间的粘附，诱导新生血管形成，最终促进胃癌的侵袭和转移[<xref ref-type="bibr" rid="scirp.15032-ref3">3</xref>] 。因此，越来越多的的研究者开始重视对基质金属蛋白酶的研究，并希望找到合适的拮抗剂为胃癌的治疗提供一条新的途径。</p></sec><sec id="s4"><title>2. 基质金属蛋白酶简介</title><sec id="s4_1"><title>2.1. MMPs的结构</title><p>MMPs是一类具有Zn<sup>2+</sup>依赖性的内源性蛋白水解酶，它们由正常组织细胞(结缔组织细胞、内皮细胞和巨噬细胞等)和肿瘤细胞以前酶形式分泌。目前MMPs家族已命名至MMP-28，它们大小各异，底物不尽相同[<xref ref-type="bibr" rid="scirp.15032-ref4">4</xref>] 。所有MMPs均由具有同源性的10个外显子和9个内含子组成(MMP-2、MMP-9另外还有3个外显子)，具有以下类似的基本结构[<xref ref-type="bibr" rid="scirp.15032-ref5">5</xref>] ，即：1) 信号肽域：除MMP-14外均含有，为疏水信号肽序列，它将翻译后的新生肽链引导至胞浆；2) 前肽域：前肽区内含有保守的Pro-Arg-Cys-Gly-Val/Asn-Pro-Asp (PRCGV/NPD)序列，它通过阻断锌离子活性中心与底物结合，维持MMPs酶原的稳定，当激活剂脱去该区域即被活化；3) 催化域：包括Zn<sup>2+</sup>结合区、Ca<sup>2+</sup>结合区和高度保守的蛋氨酸结构，在MMPs的催化过程中有重要作用；4) 铰链域：富含脯氨酸，用来连接催化域和COOH末端域；5) 羧基末端域：血红素结合蛋白样或纤维结合素样的COOH末端域，决定底物的特异性；6) 对于模型MMP还有跨膜区，维持酶与细胞膜之间的稳定。</p></sec><sec id="s4_2"><title>2.2. MMPs的分类</title><p>根据MMPs作用底物、分子结构可分为6组[<xref ref-type="bibr" rid="scirp.15032-ref6">6</xref>] ：1) 胶原酶：MMP-1、MMP-8和MMP-13等，主要底物为：纤维胶原I、II、III、VII等；2) 明胶酶：MMP-2和MMP-9等，主要底物为：明胶、弹性蛋白和胶原V、VI等；3) 间质溶解素：MMP-3、MMP-7和MMP-10等，主要底物为：非纤维胶原、层粘连蛋白和弹性蛋白等；4) 膜型基质金属蛋白酶：MMP-14、MMP-15、MMP-16、MMP-17、MMP-24和MMP-25等，主要底物为：明胶酶A前体；5) 基质溶解酶：基质溶解因子1 (MMP-7)和基质溶解因子2 (MMP-26)等，主要底物：非纤维胶原、层粘连蛋白和蛋白多糖中心蛋白等；6) 其他无法归入上述5组的MMPs。</p></sec><sec id="s4_3"><title>2.3. MMPs的调节</title><p>MMPs的表达和活性受到三个方面的调节[<xref ref-type="bibr" rid="scirp.15032-ref7">7</xref>] ：1) 合成的调控：MMPs基因转录受很多因素影响，生长因子和细胞因子是其中最主要的调节因素，除此之外，一些粘附分子、致癌剂等也可以调控转录。研究发现，EGF、TNF-a、类花生四烯酸可增强MMPs的转录，而IFN-γ、IL-1β、IL-6、bFGF、TGF-β、胶原酶-1等则可以抑制其转录；2) 活化的调控：MMPs是以酶原形式分泌，其活化需要血清蛋白酶介导的级联反应切断活性前区片段。纤维蛋白溶酶及尿激酶型纤维蛋白溶酶原等丝氨酸蛋白激酶一直被认为是MMP重要的激活剂；3) 抑制剂的调控：MMPs组织特异性抑制剂(TIMP)常以1:1的分子数与MMPs连接成非共价复合物，从而抑制MMPs的活性。生理状态下，MMPs的精细调控机制保证了机体内细胞迁移和细胞外基质的重构，而当细胞发生癌变，调节失控时，则促进了肿瘤细胞的侵袭和转移。</p></sec></sec><sec id="s5"><title>3. 胃癌侵袭和转移的过程</title><p>侵袭是指恶性肿瘤细胞在质和量方面异常地分布于组织间隙的现象；是肿瘤细胞粘连、酶降解、移动、基质内增殖等一系列过程的表现。转移是指恶性肿瘤细胞脱离其原发部位，通过各种渠道转运到不连续的靶组织继续增殖生长，形成同样性质肿瘤的过程，并且侵袭是转移的前提和关键步骤。胃癌发生侵袭和转移侵犯，至少要经过脱落粘附、降解细胞外基质和基底膜、迁移等步骤[<xref ref-type="bibr" rid="scirp.15032-ref8">8</xref>] 。</p><p>胃黏膜上皮发生癌变时，常伴随着细胞表面粘附分子表达的异常，进而使得肿瘤细胞之间的粘附能力降低，而肿瘤细胞与细胞外基质和内皮细胞间的粘附能力增加。在癌细胞与细胞外基质和基底膜紧密接触4~8小时后，癌细胞分泌并诱导宿主细胞(如纤维细胞和巨噬细胞)产生蛋白水解酶，溶解细胞外基质和基底膜，使基底膜产生局部缺损[<xref ref-type="bibr" rid="scirp.15032-ref9">9</xref>] 。在细胞外基质和基底膜结构改变后，肿瘤细胞在各种细胞因子诱导下，通过阿米巴运动迁移进入基质，进一步溶解结缔组织，在间质中移动，完成整个浸润过程。当肿瘤细胞到达血管或淋巴管壁时，以同样的方式穿过管壁的基底膜进入管腔，同时启动血小板聚集，形成小瘤位，到达靶组织，再穿透毛细血管或淋巴管壁，向周围间质浸润，在基质中不断增生，最终形成新的继发瘤[<xref ref-type="bibr" rid="scirp.15032-ref10">10</xref>] 。内皮细胞可以通过缺损的基底膜迁移并增殖，在层粘连蛋白的作用下有序排列，形成新的血管。癌细胞在侵袭和转移过程中，需两次浸润周围组织和穿越血管或淋巴管的基底膜[<xref ref-type="bibr" rid="scirp.15032-ref11">11</xref>] 。</p></sec><sec id="s6"><title>4. MMPs参与胃癌生物学特性的调控</title><p>MMPs通过影响细胞外基质降解平衡而广泛参与生理和病理过程，它不仅与胚胎发育和月经周期等有关，而且还与风湿性关节炎及肝肾纤维化等疾病有关[<xref ref-type="bibr" rid="scirp.15032-ref12">12</xref>] 。更为重要的是，MMPs活性的增加与多种恶性肿瘤的生物学特性也密切相关，它通过降解细胞外基质和基底膜成分、调节肿瘤细胞的粘附、促进细胞的生长等作用来促进肿瘤细胞的转移。</p><sec id="s6_1"><title>4.1. 降解细胞外基质</title><p>细胞外基质是细胞生存的重要内环境，主要由胶原蛋白、弹性蛋白、糖蛋白和蛋白多糖组成，不同组织器官各种组成成分比例不同，其主要作用是把细胞连接在一起，支撑和维持组织的生理结构和功能。基底膜是一种以IV型胶原为骨架，并有层粘连蛋白、纤维粘连蛋白和接触蛋白等共同组成的网状膜结构[<xref ref-type="bibr" rid="scirp.15032-ref13">13</xref>] 。胃癌侵袭和转移的关键步骤是降解肿瘤周围的基质，MMPs能通过破坏基质的降解平衡而促进癌细胞突破基底膜和细胞外基质构成的组织学屏障，从而侵袭周围组织和转移至远处组织[<xref ref-type="bibr" rid="scirp.15032-ref14">14</xref>] 。研究者在研究降解基底膜胶原蛋白酶的实验中，证实了MMP-2能降解天然VI胶原[<xref ref-type="bibr" rid="scirp.15032-ref15">15</xref>] 。其后众多研究证实了MMP活性上调与肿瘤侵袭转移能力之间的关系。目前MMPs被公认为是降解细胞外基质最重要的一类蛋白酶。</p></sec><sec id="s6_2"><title>4.2. 促进血管生成</title><p>新生血管可以为胃癌细胞的增殖、侵袭和转移提供足够的氧气和营养物质，对于胃癌的进展有重要作用。新生血管形成的过程包括毛细血管内皮层下基底膜降解、内皮细胞迁移和增殖、新生血管形成和新的基底膜形成等一系列过程，MMPs通过对基底膜的降解、促进多种血管生长的调节因子(如：VEGF，bFGF，TGF-β及TGF-α等)的合成和释放，体外实验表明：在血管形成与肿瘤转移的过程中，内源性或人工合成的MMPs都能刺激血管生成[<xref ref-type="bibr" rid="scirp.15032-ref16">16</xref>] 。有报道指出MMP-2、MMP-7及MMP-9在胃癌组织中的表达与新生血管的密度呈明显的正相关 [<xref ref-type="bibr" rid="scirp.15032-ref17">17</xref>] 。Nisato等 [<xref ref-type="bibr" rid="scirp.15032-ref18">18</xref>] 的研究发现，MMP-14可与整合素avβ3作用并促进血管的生成。由此可见，MMPs在胃癌血管形成中扮演着非常重要的角色。</p></sec><sec id="s6_3"><title>4.3. 调节细胞之间的粘附</title><p>肿瘤细胞之间及其与宿主细胞之间的粘附在肿瘤的侵袭与转移中起重要作用。肿瘤细胞要成功地完成转移过程，必须具有适当的粘附、脱粘附的能力，MMPs的活化将加强整合素与其配体的结合，从而改变细胞与细胞之间、细胞与细胞外基质之间的粘附功能，对肿瘤细胞在细胞外基质中的移行产生影响 [<xref ref-type="bibr" rid="scirp.15032-ref19">19</xref>] 。膜型基质金属蛋白酶1 (MT1-MMP）能促进整合素ανβ的高度表达，并能有效地与MMP-2的C末端结合并活化MMP-2，促使瘤细胞在血管内聚集及穿出血管形成转移灶 [<xref ref-type="bibr" rid="scirp.15032-ref20">20</xref>] 。</p></sec><sec id="s6_4"><title>4.4. MMPs促进肿瘤细胞的生长</title><p>MMPs破坏正常的基质后可以激活一些生长因子(如EGF、FGF和IGFs等)的表达，进而促进肿瘤生长。增长的肿瘤组织和间质又会释放更多的MMPs激活相应生长因子的表达，形成恶性循环 [<xref ref-type="bibr" rid="scirp.15032-ref21">21</xref>] 。虽然MMPs通过降解细胞外基质也可以促进凋亡，但由于肿瘤细胞能逃避正常的细胞凋亡调控，使得MMPs选择性地促进肿瘤细胞周围的一些正常的细胞凋亡，正常组织和细胞被破坏，反过来又促进了肿瘤细胞的生长 [<xref ref-type="bibr" rid="scirp.15032-ref22">22</xref>] 。</p></sec></sec><sec id="s7"><title>5. MMPs在胃癌中的表达</title><p>许多研究表明MMP表达和活性水平与胃癌细胞侵袭和转移表型呈正相关，将MMP-7及MT1-MMP的cDNA导入无或弱转移潜能的细胞后，其恶性表型大大提高 [<xref ref-type="bibr" rid="scirp.15032-ref23">23</xref>] 。研究者在研究胃癌细胞株MMP-2表达时发现：浸润型细胞株表达MMP-2，而非浸润型细胞株不表达MMP-2；并且发现MMP-2表达阳性细胞株来源病人的预后明显差于阴性者 [<xref ref-type="bibr" rid="scirp.15032-ref24">24</xref>] 。</p><p>胃癌组织研究表明：MMP-2和MMP-9在胃癌组织中的表达和活性水平明显高于周围正常粘膜，且表达与胃癌分期、淋巴转移分级呈正相关，而与其抑制物TIMP-2表平呈负相关 [<xref ref-type="bibr" rid="scirp.15032-ref25">25</xref>] 。进一步通过三明治酶免疫分析及明胶酶谱学检测发现：MMP-2主要表达于进展期胃癌，并与肿瘤的血管侵犯密切相关，其前体的激活是胃癌细胞扩散的关键环节 [<xref ref-type="bibr" rid="scirp.15032-ref26">26</xref>] 。同样有研究发现：胃癌中MMP-7的活性明显高于正常组织，并且其表达强度与肿瘤浸润深度、淋巴结转移和脉管侵犯以及5年生存率密切相关， MMP-7高表达的胃癌患者预后较差 [<xref ref-type="bibr" rid="scirp.15032-ref27">27</xref>] 。</p></sec><sec id="s8"><title>6. MMPs在胃癌中的临床应用</title><p>MMPs的活性与胃癌的侵袭、转移之间存在明显的正相关，因此通过合成MMPs的拮抗剂抑制胃癌的转移，已成为胃癌治疗研究的重要内容。人工合成的MMPs抑制剂按其作用机理分为三大类：1) 鳌和MMPs催化中心Zn<sup>2+</sup>抑制其活性。这一类包括早期广谱MMPs抑制剂，如batimastat和Marimastat，研究发现marimastat能降低胃癌小鼠MGLVAI (mice bearing the human gastric tumor) 48%的肿瘤生长率 [<xref ref-type="bibr" rid="scirp.15032-ref28">28</xref>] ，Batimastat可明显增强多西紫杉醇的抗肿瘤转移作用。但由于其口服生物利用率低，主要用于胸腹腔的直接注射控制浆膜腔积液 [<xref ref-type="bibr" rid="scirp.15032-ref29">29</xref>] 。随后出现了口服生物利用度好、便于长期服用的MMP抑制剂，如BB2516；目前开发了针对MMP-2及MMP-9的选择性抑制剂，如AG3340、CGS27023A等，都已进入临床试验阶段。2) 阻断MMP酶原活化,。染料木黄酮和OPB-3206可以通过抑制MMPs酶原的活化来抑制MMPs的活性。3) 在基因水平阻断MMPs合成。PD098059可抑制ERK1/ERK2活性，从而抑制MMP-9、基质溶解素-2和I型胶原酶等水解酶的基因转录。</p><p>最近，有学者试图从中草药中提取MMPs抑制剂，他们发现中药黄芪和莪术配伍可以抑制胃癌MKN-45细胞中MMP-2和VFGF的表达，从而抑制肿瘤细胞的生长和转移 [<xref ref-type="bibr" rid="scirp.15032-ref30">30</xref>] 。胡晓慧等 [<xref ref-type="bibr" rid="scirp.15032-ref31">31</xref>] 制备出能与MMP-2结合并具有活性功能的单克隆抗体，命名为SZ-117，该抗体有望成为一种新的抗肿瘤物质。但需指出，胃癌一旦发现多已进入晚期，已发生侵袭和转移，因此MMPs抑制剂在实际控制肿瘤发展中的疗效还需要将来在临床进一步验证。</p></sec><sec id="s9"><title>7. 前景与展望</title><p>综上所述，MMPs是一类与胃癌的侵袭和转移密切相关的蛋白水解酶，它们通过降解肿瘤细胞外基质和基底膜、促进血管的生成、调节细胞间的粘附等作用促进癌细胞的转移，但其中具体的分子机制以及MMPs家族成员中的相互调控关系仍未完全阐明。通过对MMPs作用机制的深入剖析，将有助于研究者对胃癌侵袭转移机制的进一步认识，从而为胃癌治疗提供方向性的目标。目前的研究结果也提示我们可通过阻断的MMPs作用来抑制胃癌的侵袭与转移。这一研究领域的深入，有望为临床治疗胃癌提供新的策略与方法。</p></sec><sec id="s10"><title>文章引用</title><p>熊亚立,向 征, (2015) 基质金属蛋白酶与胃癌侵袭和转移的研究进展The Research Progress of Matrix Metalloproteinases in Invasion and Metastasis of Gastric Cancer. 世界肿瘤研究,02,21-26. doi: 10.12677/WJCR.2015.52004</p></sec><sec id="s11"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.15032-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Sampieri, C.L., León-Córdoba, K. and Remes-Troche, J.M. (2013) Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers. Journal of Cancer Research and Therapeutics, 9, 356-363.</mixed-citation></ref><ref id="hanspub.15032-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, M., Zhu, G.Y., Gao, H.Y., et al. (2011) Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma. Journal of Surgical Oncology, 103, 243-247.</mixed-citation></ref><ref id="hanspub.15032-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Jiao, F., Jin, Z., Wang, L. and Wang, L. (2013) Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma. Biomed Reports, 1, 819-827.</mixed-citation></ref><ref id="hanspub.15032-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Gencer, S., Cebeci, A. and Irmak-Yazicioglu, M.B. (2013) Matrix metalloproteinase gene expressions might be oxidative stress targets in gastric cancer cell lines. Chinese Journal of Cancer Research, 25, 322-333.</mixed-citation></ref><ref id="hanspub.15032-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hashimoto, H., Takeuchi, T., Komatsu, K., et al. (2011) Structural basis for matrix metalloproteinase-2 (MMP-2)-se- lective inhibitory action of β-amyloid precursor protein-derived inhibitor. The Journal of Biological Chemistry, 286, 33236-33243.</mixed-citation></ref><ref id="hanspub.15032-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Visse, R. and Nagase, H. (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circulation Research, 92, 827-839.</mixed-citation></ref><ref id="hanspub.15032-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Maradni, A., Khoshnevisan, A., Mousavi, S.H., et al. (2013) Role of matrix metalloproteinases (MMPs) and MMP inhibitors on intracranial aneurysms: A review article. Medical Journal of the Islamic Republic of Iran, 27, 249-254.</mixed-citation></ref><ref id="hanspub.15032-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Al-Batran, S.E., Pauligk, C., Wirtz, R., et al. (2012) The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Annals of Oncology, 23, 1699-1705.</mixed-citation></ref><ref id="hanspub.15032-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Deryugina, E.I. and Quigley, J.P. (2010) Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions. Biochimica et Biophysica Acta, 1803, 103-120.</mixed-citation></ref><ref id="hanspub.15032-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kang, M.H., Oh, S.C., Lee, H.J., et al. (2011) Metastatic function of BMP-2 in gastric cancer cells: The role of PI3K/ AKT, MAPK, the NF-κB pathway, and MMP-9 expression. Experimental Cell Research, 317, 1746-1762.</mixed-citation></ref><ref id="hanspub.15032-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Jin, X., Zhu, Z. and Shi, Y. (2014) Metastasis mechanism and gene/protein expression in gastric cancer with distant organs metastasis. Bulletin du Cancer, 101, 1-12.</mixed-citation></ref><ref id="hanspub.15032-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Amălinei, C., Căruntu, I.D., Giuşcă, S.E. and Bălan, R.A. (2010) Matrix metalloproteinases involvement in pathologic conditions. Romanian Journal of Morphology and Embryology, 51, 215-228.</mixed-citation></ref><ref id="hanspub.15032-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sillat, T., Saat, R., Pöllänen, R., Hukkanen, M., Takagi, M. and Konttinen, Y.T. (2012) Basement membrane collagen type IV expression by human mesenchymal stem cells during adipogenic differentiation. Journal of Cellular and Molecular Medicine, 16, 1485-1495.</mixed-citation></ref><ref id="hanspub.15032-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Mroczko, B., Lukaszewicz-Zając, M., Gryko, M., Kędra, B. and Szmitkowski, M. (2011) Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer. Folia Histochemica et Cytobiologica, 49, 125-131.</mixed-citation></ref><ref id="hanspub.15032-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Liotta, L.A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C.M. and Shafie, S. (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 284, 67-68.</mixed-citation></ref><ref id="hanspub.15032-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ferretti, G., Fabi, A., Carlini, P., Papaldo, P., Cordiali Fei, P., Di Cosimo, S., et al. (2005) Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology, 69, 35-43.</mixed-citation></ref><ref id="hanspub.15032-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Gerstein, E.S., Sini, L., Ryabov, A.B., Dvorova, E.K., Yurchenko, A.A., Stilidi, I.S., et al. (2009) Comparative enzyme immunoassay of matrix metalloproteinases-2, -7, -9 and their tissue inhibitor-2 in tumors and plasma of patients with gastric cancer. Bulletin of Experimental Biology and Medicine, 148, 899-902.</mixed-citation></ref><ref id="hanspub.15032-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Nisato, R.E., Hosseini, G., Sirrenberg, C., Butler, G.S., Crabbe, T., Docherty, A.J.P., et al. (2005) Dissecting the role of matrix metalloproteinases (MMPs) and integrin αvβ3 in angiogenesis in vitro: Absence of hemopex in C domain bioactivity, but membrane-type1-MMP and αvβ3 are critical. Cancer Research, 65, 9377-9387.</mixed-citation></ref><ref id="hanspub.15032-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Shih, Y.W., Chien, S.T., Chen, P.S., Lee, J.H., Wu, S.H. and Yin, L.T. (2010) α-mangostin suppresses phorbol 12-myristate 13-acetate-induced MMP-2/MMP-9 expressions via αvβ3 integrin/FAK/ERK and NF-κB signaling pathway in human lung adenocarcinoma A549 cells. Cell Biochemistry and Biophysics, 58, 31-44.</mixed-citation></ref><ref id="hanspub.15032-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Temma, T., Sano, K., Kuge, Y., Kamihashi, J., Takai, N., Ogawa, Y. and Saji, H. (2009) Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant trumors. Biological and Pharmaceutical Bulletin, 32, 1272-277.</mixed-citation></ref><ref id="hanspub.15032-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Perng, D.W., Chang, K.T., Su, K.C., Wu, Y.C., Chen, C.S., Hsu, W.H., et al. (2011) Matrix metalloprotease-9 induces transforming growth factor-β(1) production in airway epithelium via activation of epidermal growth factor receptors. Life Sciences, 89, 204-212.</mixed-citation></ref><ref id="hanspub.15032-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Siqueira, A.S., Carvalho, M.R., Monteiro, A.C., Freitas, V.M., Jaeger, R.G. and Pinheiro, J.J.V. (2010) Matrix metalloproteinases, TIMPs and growth factors regulating ameloblastoma behavior. Histopathology, 57, 128-137.</mixed-citation></ref><ref id="hanspub.15032-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Saito, Y., Sekine, W., Sano, R., Komatsu, S., Mizuno, H., Katabami, K., et al. (2010) Potentiation of cell invasion and matrix metalloproteinase production by α3β1 integrin-mediated adhesion of gastric carcinoma cells to laminin-5. Clinical &amp; Experimental Metastasis, 27, 197-205.</mixed-citation></ref><ref id="hanspub.15032-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Jang, K.J., Son, I.S., Shin, D.Y., Yoon, H.M. and Choi, Y.H. (2011) Anti-invasive activity of ethanol extracts of Ganoderma lucidum through tightening of tight junctions and inhibition of matrix metalloproteinase activities in human gastric carcinoma cells. Journal of Acupuncture and Meridian Studies, 4, 225-235.</mixed-citation></ref><ref id="hanspub.15032-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Shim, K.N., Jung, S.A., Joo, Y.H. and Yoo, K. (2007) Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. Journal of Gastroenterology, 42, 120-128.</mixed-citation></ref><ref id="hanspub.15032-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Partyka, R., Gonciarz, M., Jałowiecki, P., Kokocińska, D. and Byrczek, T. (2012) VEGF and metalloproteinase 2 (MMP 2) expression in gastric cancer tissue. Medical Science Monitor, 18, 130-134.</mixed-citation></ref><ref id="hanspub.15032-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Koskensalo, S., Mrena, J., Wiksten, J.P., Nordling, S., Kokkola, A., Hagström, J. and Haglund, C. (2010) MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumor Biology, 31, 149-155.</mixed-citation></ref><ref id="hanspub.15032-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Lenger, J., Kaschani, F., Lenz, T., Dalhoff, C., Villamor, J.G., Köster, H., et al. (2012) Labeling and enrichment of Arabidopsis thaliana matrix metalloproteases using an active-site directed, marimastat-based photoreactive probe. Bioorganic &amp; Medicinal Chemistry, 20, 592-596.</mixed-citation></ref><ref id="hanspub.15032-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">van Wijngaarden, J., Snoeks, T.J., van Beek, E., Bloys, H., Kaijzel, E.L., et al. (2010) An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: Actions of TNP-470, marimastat and the tubulin-binding agent Ang-510. Biochemical and Biophysical Research Communications, 391, 1161-1165.</mixed-citation></ref><ref id="hanspub.15032-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">骆殊, 沈洪, 朱学军, 刘丽, 李春婷, 刘亚军 (2009) 黄芪、莪术配伍对胃癌MKN-45细胞COX-1, COX-2 , NF-κB, VEGF, MMP-2表达的影响. 现代中西医结合杂志, 4, 351-353.</mixed-citation></ref><ref id="hanspub.15032-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">胡晓慧, 沈飞, 董宁征, 李佩霞, 阮长耿 (2005) 抗人基质金属蛋白酶-2的单抗制备及功能研究. 中国病理生理杂志, 5, 876-881.</mixed-citation></ref></ref-list></back></article>